Most Read Articles
5 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
3 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Maintenance therapy with difluoromethylornithine safe, effective in high-risk neuroblastoma

09 Oct 2018

Difluoromethylornithine (DFMO) maintenance medication in high-risk neuroblastoma (HRNB) patients is associated with better survival outcomes, a recent study has shown.

The study included HRNB patients with histologically confirmed disease who took maintenance DFMO to prevent relapse following completion of standard therapy (stratum 1; n=101; mean age 3.5 years; 56 percent male) or after salvage therapy for relapsed disease (stratum 2; n=39; mean age 3.2 years; 72 percent male).

Over a median follow-up period of 3.5 years, participants in stratum 1 demonstrated a mean 2-year event-free survival rate of 84.4±4 percent. Overall survival was likewise high at 97±2 percent. Survival rates remained high even in patients with high-risk features such as status of the MYCN gene.

In the subset of stratum 1 participants who were given DFMO after the completion of the Children’s Oncology Group antibody clinical trial, event-free and overall survival rates were also high (86±4 percent and 97±2 percent).

In stratum 2, the 2-year event-free and overall survival rates were low at 51±8 percent and 84±6 percent, respectively. These values were lower in patients with relapsed disease (35±11 percent and 80±9 percent, respectively) and higher in those with primary refractory disease (68±11 percent and 89±7 percent, respectively).

In terms of safety, no serious adverse events were reported. Majority (67 percent) of the patients reported no treatment-related adverse events. Grade 2–3 transaminitis was the most common adverse event, and none of the cases required suspension of the DFMO treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
3 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.